IP Library Granted Patent US 8,183,009
Granted Patent B2
US 8,183,009 · App. 12/690,529 · Granted May 22, 2012

Assaying cellular markers for the evaluation of tumors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,009
App. No.
12/690,529
Granted
May 22, 2012
Kind
B2
Abstract

An improved system for assaying expression of various markers, factors or antigens on the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents.

Claims (10)

1. A method for evaluating a tumor for cancer state or cancer progression comprising the steps of:

mechanically separating a patient's tumor tissue specimen into multicellular tissue explants, wherein the explants are not dissociated cell suspensions, and the explants comprise malignant cells and stromal cells;

growing a tissue culture monolayer(s) from said explants in culture medium; and

assaying cells of said monolayer by immunohistochemistry to identify one or more membrane-bound markers indicative of cancer state or cancer progression, thereby evaluating the tumor for cancer state or cancer progression.

2. The method of claim 1 , wherein a profile of said membrane bound markers is determined.

3. The method of claim 1 , wherein the multicellular tissue explants have smooth cut edges.

4. The method of claim 3 , wherein said smooth cut edges are created by systematic mincing in a scissor-like motion.

5. The method of claim 1 , wherein the multicellular tissue explants have a size distribution of about 0.25 mm 3 to about 1.4 mm 3 .

6. The method of claim 5 , wherein the multicellular tissue explants have a size of about 1 mm 3 .

7. The method of claim 1 , wherein the tumor tissue specimen is selected from the group consisting of renal carcinoma, breast cancer, mesothelioma and ovarian tumor.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2016
From: HELOMICS CORPORATION
To: CYTOMICS, INC.
Reel/Frame 040529/0022 →
CHANGE OF NAME Recorded Dec 15, 2014
From: PRECISION THERAPEUTICS, INC.
To: HELOMICS CORPORATION
Reel/Frame 034638/0930 →
SECURITY AGREEMENT Recorded Mar 23, 2012
From: PRECISION THERAPEUTICS, INC.
To: COWEN HEALTHCARE ROYALTY PARTNERS II, L.P.
Reel/Frame 027922/0459 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2010
From: KORNBLITH, PAUL L.
To: PRECISION THERAPEUTICS, INC.
Reel/Frame 025017/0421 →